Theory Paper IIIDrNB Cardiology – Theory Notes
CATHETER ABLATION OF VENTRICULAR TACHYCARDIA: CURRENT STATUS
IPATHOPHYSIOLOGY AND THE MYOCARDIAL SUBSTRATE DIVIDE
- Ischemic Cardiomyopathy (ICM — Post-Myocardial Infarction Scar):
- Mechanism: Anatomical Macro-Reentry through surviving bundles of viable myocytes insulated by dense collagen scar (forming slow-conduction critical isthmus channels with entry, central, and exit sites).
- Anatomical Location and Access: Follows the wavefront of coronary occlusion—predominantly subendocardial (progressing toward the epicardium), making the substrate directly accessible via endocardial catheter ablation (via retrograde transaortic and/or transseptal LV access) with high acute and long-term success (70 to 85 percent).
- Non-Ischemic Cardiomyopathy (NICM — DCM, Sarcoidosis, Myocarditis, ARVC, Chagas):
- Mechanism: Macro-reentry around patchy, non-confluent replacement fibrosis.
- Anatomical Location and Access: Scars cluster preferentially in two regions: (1) Perivalvular basal anteroseptal (interventricular septum) or (2) Basal inferolateral mid-myocardium and subepicardium (sparing the subendocardium). Consequently, endocardial RF lesions often fail to reach the circuit, requiring combined endocardial and percutaneous subxiphoid epicardial ablation (Sosa technique) or bipolar/needle/alcohol ablation, with lower long-term freedom from VT (50 to 65 percent).
- Idiopathic Ventricular Tachycardia (Structurally Normal Hearts):
- Outflow Tract VT (RVOT [80%] & LVOT/Aortic Cusps [20%]): Driven by cAMP-mediated triggered activity (Delayed Afterdepolarizations [DADs]); LBBB morphology with inferior axis (+90 degrees); sensitive to vagal maneuvers, Adenosine, Beta-blockers, and Verapamil.
- Idiopathic Left Ventricular Fascicular VT (Belhassen VT): Driven by calcium-channel-dependent macro-reentry involving the Left Posterior Fascicle (90%) and abnormal Purkinje tissue; narrow QRS (120–140 ms) RBBB morphology with superior Left Axis Deviation (or Left Anterior Fascicle: RBBB + Right Axis Deviation); uniquely Verapamil-sensitive.
- Outcome: Catheter ablation is definitively curative in >90 to 95 percent (Class I first-line).
IIEVOLUTION OF MAPPING TECHNIQUES IN STRUCTURAL HEART DISEASE
- Limitations of Activation and Entrainment Mapping During VT: Classical activation mapping (finding mid-diastolic potentials) and concealed entrainment (pacing during VT with post-pacing interval minus tachycardia cycle length <=30 ms and stimulus-to-QRS = electrogram-to-QRS) require the patient to tolerate sustained VT. However, >70 to 80 percent of scar-related VTs are hemodynamically unstable, multiple, or non-inducible under anesthesia.
- Modern Gold Standard — Sinus-Rhythm / Paced 3D Substrate Mapping:
- Bipolar and Unipolar Voltage Mapping: Using high-density multipolar mapping catheters (PentaRay, OctaRay, HD Grid), Bipolar voltage <= 0.5 mV defines dense endocardial scar, 0.5 to 1.5 mV defines the scar border zone, and >1.5 mV defines normal myocardium. Crucially, a normal endocardial bipolar voltage (>1.5 mV) with a reduced Unipolar LV voltage (<8.3 mV; or <5.5 mV in the RV) unmasks deep intramural or epicardial scar!
- Functional Substrate Targets (ILAM, Late Potentials, LAVA, and Core Isolation): Operators target Late Potentials (LPs) (potentials occurring after the surface QRS offset), Local Abnormal Ventricular Activities (LAVAs) (high-frequency fractionated potentials decoupled by extrastimuli), and Isochronal Late Activation Mapping (ILAM) deceleration zones (“Scar Homogenization / Dechanneling”), achieving complete non-inducibility of any VT on programmed electrical stimulation (the procedural endpoint) without prolonged hemodynamic instability.
- Pre-Procedural Contrast CT (MUSIC / inHeart) and Late Gadolinium CMR Integration: Imports 3D CMR scar channels and CT wall-thinning/coronary/phrenic nerve anatomy directly into the 3D mapping system.
IIILANDMARK RANDOMIZED TRIALS SUPPORTING EARLY VT ABLATION
| Landmark Trial | Patient Population & Comparison | Primary Efficacy Outcome | Paradigm Impact |
|---|---|---|---|
| VANISH (2016) (NEJM) | 259 ICM patients with ICD & VT despite baseline AAD (Amiodarone or Sotalol): Catheter Ablation vs. Escalated Drug Therapy | 28% RRR in primary composite (death, VT storm, or appropriate ICD shock: 59.1% vs. 68.5%; HR 0.72; p = 0.04), driven by patients failing Amiodarone (HR 0.53) | Established Class I indication for ablation over escalating AADs when Amiodarone fails in ICM |
| VANISH2 (2024) (NEJM Nov 2024) | 416 ICM patients with VT and NO prior AAD failure: First-Line Catheter Ablation vs. First-Line Sotalol or Amiodarone | 25% RRR in primary composite (death, VT storm, appropriate ICD shock, or sustained VT: 50.7% vs. 60.6%; HR 0.75; p = 0.03) with fewer non-fatal adverse events | Proved First-Line Catheter Ablation is superior to starting Amiodarone/Sotalol in post-MI VT |
| PARTITA (2022) (Circulation) | Ischemic & Non-Ischemic ICD patients: Immediate VT Ablation after FIRST Appropriate ICD Shock vs. Standard Waiting | 89% RRR in primary composite of All-Cause Death or Worsening HF Hospitalization (4% vs. 42%; HR 0.11; p = 0.01) + fewer recurrent shocks (9% vs. 42%) | Shifted VT ablation to after the very first ICD shock to prevent HF progression and mortality |
| PAUSE-SCD (2022) (Circulation) | 121 Asian ICM, NICM, & ARVC patients (54% NICM/ARVC) undergoing ICD: Upfront Ablation at ICD Implant vs. Medical Therapy | 42% RRR in primary composite (VT recurrence, CV hospitalization, or death: 49.3% vs. 65.5%; HR 0.58; p = 0.04) | Proved early ablation efficacy in Asian NICM and ARVC cohorts |
| SURVIVE-VT (2022) & BERLIN VT (2020) | SURVIVE-VT (144 ICM): First-line Ablation vs. AAD; BERLIN VT: Preventive ablation before any shock vs. deferred until 3rd shock | SURVIVE-VT: 48% RRR in CV death, shock, HF admission, or severe treatment complication (28.2% vs. 46.6%; HR 0.52); BERLIN VT: Neutral primary endpoint (stopped early for futility) | Supports ablation at first clinical VT/shock (rather than purely prophylactic before any clinical VT) |
IVCURRENT GUIDELINE RECOMMENDATIONS (ESC 2022 VA/SCD GUIDELINES)
- Class I Recommendations (Recommended):
- Symptomatic Idiopathic Outflow Tract (RVOT) or Fascicular (Belhassen) VT: First-line therapy.
- Ischemic Cardiomyopathy with Recurrent Symptomatic Sustained Monomorphic VT or ICD Shocks Despite Chronic Amiodarone Therapy: Catheter ablation is recommended over escalating antiarrhythmic drug therapy (VANISH).
- Incessant VT or Electrical Storm resulting from sustained monomorphic VT refractory to antiarrhythmic drugs.
- Bundle-Branch Reentrant VT (BBR-VT) (seen in DCM, myotonic dystrophy, or post-aortic valve surgery; cured by ablating the Right Bundle Branch).
- Class IIa Recommendations (Should Be Considered):
- Ischemic Cardiomyopathy with Recurrent VT on Beta-Blockers or Sotalol (when Amiodarone is not desired; further strengthened by VANISH2).
- Ischemic Cardiomyopathy After a First Episode of Sustained Monomorphic VT / First Appropriate ICD Shock (PARTITA, SURVIVE-VT).
- Non-Ischemic Cardiomyopathy (DCM / ACM / ARVC) with Recurrent Symptomatic Sustained Monomorphic VT or ICD Shocks in specialized centers with epicardial ablation capability when antiarrhythmic drugs are ineffective, contraindicated, or not tolerated.
VPRACTICAL CONSIDERATIONS IN THE INDIAN CLINICAL CONTEXT
- High Prevalence of Verapamil-Sensitive Fascicular VT (Belhassen VT): In young Indian adults with structurally normal hearts, Left Posterior Fascicular VT (RBBB morphology + Left Axis Deviation + RS interval <80 ms + capture/fusion beats) is frequently misdiagnosed in emergency departments as “SVT with aberrancy” (because the QRS is relatively narrow at 120 to 140 ms and terminates with IV Verapamil while being unresponsive to Adenosine). Catheter ablation targeting purkinje potentials (P1 diastolic and P2 pre-systolic potentials) along the inferoposterior LV septum offers a >95 percent permanent cure.
- Granulomatous Substrates (Cardiac Sarcoidosis and Tuberculous Myocarditis): In India, non-ischemic monomorphic VT frequently arises from Cardiac Sarcoidosis or healed Tuberculous Myopericarditis. Active myocardial inflammation must first be excluded via 18F-FDG PET/CT and suppressed with corticosteroids/anti-tubercular therapy before attempting catheter ablation (which frequently requires combined endocardial and epicardial access).
- Late-Presenting Anterior STEMI Apical Aneurysms: Delayed STEMI reperfusion in rural India leads to large calcified LV apical aneurysms with mural thrombus; pre-procedural Contrast Echo or Cardiac CT/MRI is mandatory before endocardial LV mapping to exclude mobile LV thrombus (an absolute contraindication to endocardial LV ablation, though epicardial ablation remains feasible).
VIFRONTIER MODALITIES FOR REFRACTORY INTRAMURAL VT
- Intramural Septal Bailout Techniques: When the VT circuit is buried deep inside a thick interventricular septum (>10–15 mm), specialized techniques include half-normal (0.45%) saline irrigation (increases impedance to create deeper RF lesions), Simultaneous Unipolar or Bipolar RF Ablation (between RV and LV septal catheters), Retractable Intramyocardial Needle Ablation, Transcoronary / Transvenous Ethanol Septal Ablation, and Pulsed Field Ablation (PFA) (non-thermal electroporation that penetrates fibrous scar with relative sparing of the phrenic nerve, though coronary spasm can occur).
- Non-Invasive Stereotactic Body Radiation Therapy (SBRT / Cardiac Radioablation — ENCORE-VT): A single 25-Gray fraction of external-beam stereotactic radiotherapy guided by non-invasive ECG-imaging (ECGI) and CT/CMR reduces VT burden by >85–90% as a compassionate bailout in patients with refractory electrical storm unsuitable for catheter ablation.
Key references
- Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al.: 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death, European Heart Journal, 2022.
- Sapp JL, Wells GA, Parkash R, et al. (VANISH Investigators): Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs, New England Journal of Medicine, 2016.
- Sapp JL, Tang ASL, Parkash R, et al. (VANISH2 Investigators): Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia, New England Journal of Medicine, 2024.
- Della Bella P, Baratto F, Vergara P, et al. (PARTITA Investigators): Does Timing of Ventricular Tachycardia Ablation Affect Prognosis in Patients With an Implantable Cardioverter Defibrillator? Results From the Multicenter Randomized PARTITA Trial, Circulation, 2022.
meritmedscript.comDr. Sidhartha Mullapudi
